Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

@article{Jin2008CooperationOT,
  title={Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.},
  author={Hongkui Jin and Renhui Yang and Jed Ross and Sharon E. Fong and Richard A D Carano and Klara Totpal and David Lawrence and Zhong A. Zheng and Hartmut Koeppen and Howard Stern and Ralph H. Schwall and Avi Ashkenazi},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 23},
  pages={7733-40}
}
PURPOSE Apomab is a fully human monoclonal antibody that induces programmed cell death through the proapoptotic receptor DR5 in various cancer cells but not in normal cells. Several lung cancer cell lines express DR5 and exhibit apoptosis in response to apomab in vitro. EXPERIMENTAL DESIGN We investigated the efficacy of apomab and its interaction with chemotherapy in xenograft models based on human NCI-H460 non-small-cell lung carcinoma cells. In an established model of s.c. tumor xenografts… CONTINUE READING
28 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

A novel anti - human DR 5 antibody with tumoricidal activity induces caspasedependent and caspaseindependent cell death

  • C Chen
  • JBiol Chem
  • 2005

Similar Papers

Loading similar papers…